Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AbbVie Inc.ABBV · Entity 2800 | SVP, US COMMERCIAL OPERATIONS | April 25, 2023 | April 27, 2023 |
| Artiva Biotherapeutics, Inc.ARTV · Entity 5404 | Director | September 10, 2026 | September 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AbbVie Inc.
Report date April 25, 2023 · Filed April 27, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 35,330 |
Ending reported balance
After 2023-04-25 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-04-25 · Exercise / conversion · Acquired 6,130 · Balance 41,460 Row 2 · 2023-04-25 · Sale · Disposed 6,130 · Balance 35,330 F1: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.00 to $165.03, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $144.54 · Expires 2032-02-16 | Direct | 12,258 |
Reported balance
After 2023-04-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-04-25 · Exercise / conversion · Disposed 6,130 · Balance 12,258 F2: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.00 to $165.03, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.
Artiva Biotherapeutics, Inc.
Report date September 10, 2026 · Filed September 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.42 · Expires 2036-09-09 | Direct | 16,250 |
Reported balance
After 2026-09-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-10 · Grant · Acquired 16,250 · Balance 16,250 F1: The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2026 Filed Sep 14, 2026 20:04 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantDirector Stock Option (Right to Buy) · Derivative | 16,250 | $0.00 Strike: $10.42 | $0.00 |
DisclosureSEC source: 0001193125-26-390540 · ownership.xml · derivative · entry 1 Sorg Elaine K. · CIK 0001832571 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,250 Underlying: Common Stock · 16,250 shares Expires 2036-09-09 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting. Read SEC document |
| September 08, 2026 Filed Sep 8, 2026 21:57 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantDirector Stock Option (Right to Buy) · Derivative | 13,750 | $0.00 Strike: $10.88 | $0.00 |
DisclosureSEC source: 0001193125-26-385418 · ownership.xml · derivative · entry 1 Sorg Elaine K. · CIK 0001832571 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 13,750 shares Expires 2036-09-07 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of September 8, 2027, or the date of the Issuer's 2027 annual stockholder meeting. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 02:50 UTC | Artiva Biotherapeutics, Inc. ARTV · Entity 5404 | GrantDirector Stock Option (Right to Buy) · Derivative | 27,500 | $0.00 Strike: $4.15 | $0.00 |
DisclosureSEC source: 0001193125-26-060074 · ownership.xml · derivative · entry 1 Sorg Elaine K. · CIK 0001832571 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires 2036-02-17 F1 · derivative.exercise_date: One-third of the shares vested following the grant date, with the remaining shares vesting monthly over an additional two years following February 18, 2026. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to Buy) · Derivative | 6,130 | $144.54 Strike: $144.54 | $886,030.20 |
DisclosureSEC source: 0001415889-23-006965 · form4-04272023_050402.xml · derivative · entry 3 Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,258 Underlying: Common Stock · 6,130 shares Expires 2032-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:00 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 6,130 | $165.00 | $1,011,450.00 |
DisclosureSEC source: 0001415889-23-006965 · form4-04272023_050402.xml · nonDerivative · entry 2 Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,330 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.00 to $165.03, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 6,130 | $144.54 | $886,030.20 |
DisclosureSEC source: 0001415889-23-006965 · form4-04272023_050402.xml · nonDerivative · entry 1 Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,460 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 17, 2023 Filed Apr 19, 2023 21:00 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 500 | $162.04 | $81,020.00 |
DisclosureSEC source: 0001415889-23-006720 · form4-04192023_050401.xml · nonDerivative · entry 2 Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,330 F2 · shares: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $162.00 to $162.14, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 17, 2023 Filed Apr 19, 2023 21:00 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 6,999 | $161.64 | $1,131,318.36 |
DisclosureSEC source: 0001415889-23-006720 · form4-04192023_050401.xml · nonDerivative · entry 1 Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,830 F1 · shares: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $161.00 to $161.95, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 21:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to Buy) · Derivative | 15,002 | $93.50 Strike: $93.50 | $1,402,687.00 |
DisclosureSEC source: 0001415889-23-006301 · form4-04052023_050407.xml · derivative · entry 3 Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,002 shares Expires 2030-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 21:00 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 15,002 | $160.03 | $2,400,770.06 |
DisclosureSEC source: 0001415889-23-006301 · form4-04052023_050407.xml · nonDerivative · entry 2 Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,829 F1 · shares: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.00 to $160.05, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 21:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 15,002 | $93.50 | $1,402,687.00 |
DisclosureSEC source: 0001415889-23-006301 · form4-04052023_050407.xml · nonDerivative · entry 1 Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,831 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 22:07 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to Buy) · Derivative | 15,003 | $93.50 Strike: $93.50 | $1,402,780.50 |
DisclosureSEC source: 0001415889-23-003856 · form4-03022023_100350.xml · derivative · entry 4 Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,003 shares Expires 2030-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 22:07 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 15,003 | $155.00 | $2,325,465.00 |
DisclosureSEC source: 0001415889-23-003856 · form4-03022023_100350.xml · nonDerivative · entry 3 Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,829 Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 22:07 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 15,003 | $93.50 | $1,402,780.50 |
DisclosureSEC source: 0001415889-23-003856 · form4-03022023_100350.xml · nonDerivative · entry 2 Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,832 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 22:07 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 19,850 | $154.28 | $3,062,458.00 |
DisclosureSEC source: 0001415889-23-003856 · form4-03022023_100350.xml · nonDerivative · entry 1 Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,829 Read SEC document |
| February 21, 2023 Filed Feb 21, 2023 23:12 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to Buy) · Derivative | 15,321 | $105.92 Strike: $105.92 | $1,622,800.32 |
DisclosureSEC source: 0001415889-23-002944 · form4-02212023_110252.xml · derivative · entry 9 Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,660 Underlying: Common Stock · 15,321 shares Expires 2031-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 21, 2023 Filed Feb 21, 2023 23:12 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 8,420 | $151.29 | $1,273,861.80 |
DisclosureSEC source: 0001415889-23-002944 · form4-02212023_110252.xml · nonDerivative · entry 7 Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,679 F6 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.12 to $151.53, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 21, 2023 Filed Feb 21, 2023 23:12 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 6,901 | $150.74 | $1,040,256.74 |
DisclosureSEC source: 0001415889-23-002944 · form4-02212023_110252.xml · nonDerivative · entry 6 Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,099 F5 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.12 to $151.11, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 21, 2023 Filed Feb 21, 2023 23:12 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 15,321 | $105.92 | $1,622,800.32 |
DisclosureSEC source: 0001415889-23-002944 · form4-02212023_110252.xml · nonDerivative · entry 5 Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:12 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (Right to Buy) · Derivative | 13,166 | $0.00 Strike: $149.62 | $0.00 |
DisclosureSEC source: 0001415889-23-002944 · form4-02212023_110252.xml · derivative · entry 8 Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,166 Underlying: Common Stock · 13,166 shares Expires 2033-02-15 F7 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 4,389 on February 16, 2024, 4,389 on February 16, 2025, and 4,388 on February 16, 2026. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:12 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 3,874 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002944 · form4-02212023_110252.xml · nonDerivative · entry 4 Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,679 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:12 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 4,658 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002944 · form4-02212023_110252.xml · nonDerivative · entry 3 Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,805 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:12 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 6,861 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002944 · form4-02212023_110252.xml · nonDerivative · entry 2 Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,147 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:12 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 29,410 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002944 · form4-02212023_110252.xml · nonDerivative · entry 1 Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,286 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| March 01, 2022 Filed Mar 1, 2022 23:11 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 700 | $149.07 | $104,351.03 |
DisclosureSEC source: 0001179110-22-001837 · edgar.xml · nonDerivative · entry 4 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,876 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.93 to $149.38 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2022 Filed Mar 1, 2022 23:11 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 3,451 | $148.59 | $512,783.05 |
DisclosureSEC source: 0001179110-22-001837 · edgar.xml · nonDerivative · entry 3 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,576 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.93 to $148.91 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2022 Filed Mar 1, 2022 23:11 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 2,333 | $147.59 | $344,332.60 |
DisclosureSEC source: 0001179110-22-001837 · edgar.xml · nonDerivative · entry 2 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,027 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.93 to $147.88 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 23:11 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 11,125 | $149.54 | $1,663,632.50 |
DisclosureSEC source: 0001179110-22-001837 · edgar.xml · nonDerivative · entry 1 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,360 Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:42 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (Right to Buy) · Derivative | 18,388 | $0.00 Strike: $144.54 | $0.00 |
DisclosureSEC source: 0001179110-22-001518 · edgar.xml · derivative · entry 6 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,388 Underlying: Common Stock · 18,388 shares Expires 2032-02-16 F6 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 6,130 on February 17, 2023, 6,129 on February 17, 2024, and 6,129 on February 17, 2025. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:42 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 10,377 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001518 · edgar.xml · nonDerivative · entry 5 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,485 F5 · shares: Represents shares of AbbVie common stock issued under a cliff vesting restricted stock unit award granted to the reporting person on February 17, 2022. The shares will vest in their entirety on the third anniversary of the grant date, subject to the reporting person's continued employment at AbbVie on such date. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:42 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 4,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001518 · edgar.xml · nonDerivative · entry 4 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,108 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:42 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 6,861 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001518 · edgar.xml · nonDerivative · entry 3 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,033 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:42 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 2,530 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001518 · edgar.xml · nonDerivative · entry 2 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,172 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:42 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 11,642 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001518 · edgar.xml · nonDerivative · entry 1 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,642 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| December 13, 2021 Filed Dec 14, 2021 22:01 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 3,229 | $125.85 | $406,369.65 |
DisclosureSEC source: 0001179110-21-010958 · edgar.xml · nonDerivative · entry 3 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| December 13, 2021 Filed Dec 14, 2021 22:01 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 3,229 | $125.85 | $406,369.65 |
DisclosureSEC source: 0001179110-21-010958 · edgar.xml · nonDerivative · entry 2 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,229 Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 22:01 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 5,137 | $124.15 | $637,758.55 |
DisclosureSEC source: 0001179110-21-010958 · edgar.xml · nonDerivative · entry 1 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,458 Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 22:08 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to buy) · Derivative | 7,080 | $0.00 Strike: $114.36 | $0.00 |
DisclosureSEC source: 0001179110-21-008421 · edgar.xml · derivative · entry 4 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,080 shares Expires 2028-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 22:08 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 7,080 | $120.00 | $849,600.00 |
DisclosureSEC source: 0001179110-21-008421 · edgar.xml · nonDerivative · entry 3 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,595 Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 22:08 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 7,080 | $114.36 | $809,668.80 |
DisclosureSEC source: 0001179110-21-008421 · edgar.xml · nonDerivative · entry 2 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 23, 2021 Filed Aug 25, 2021 22:08 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 6,000 | $120.00 | $720,000.00 |
DisclosureSEC source: 0001179110-21-008421 · edgar.xml · nonDerivative · entry 1 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,595 Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 01:30 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 4,221 | $108.61 | $458,436.90 |
DisclosureSEC source: 0001179110-21-002603 · edgar.xml · nonDerivative · entry 3 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,595 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.35 to $108.83 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 01:30 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 4,219 | $108.61 | $458,205.34 |
DisclosureSEC source: 0001179110-21-002603 · edgar.xml · nonDerivative · entry 2 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,816 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.35 to $108.83 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 28, 2021 Filed Mar 3, 2021 01:30 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 6,716 | $107.74 | $723,581.84 |
DisclosureSEC source: 0001179110-21-002603 · edgar.xml · nonDerivative · entry 1 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,035 Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 23:28 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 5,192 | $0.00 Strike: $79.02 | $0.00 |
DisclosureSEC source: 0001179110-21-002251 · edgar.xml · derivative · entry 6 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,192 Underlying: Common Stock · 5,192 shares Expires 2029-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 23:28 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (right to buy) · Derivative | 15,003 | $0.00 Strike: $93.50 | $0.00 |
DisclosureSEC source: 0001179110-21-002251 · edgar.xml · derivative · entry 5 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,005 Underlying: Common stock · 15,003 shares Expires 2030-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 23:28 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 200 | $105.28 | $21,056.00 |
DisclosureSEC source: 0001179110-21-002251 · edgar.xml · nonDerivative · entry 4 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,751 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.26 to $105.31, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 23:28 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 19,995 | $104.71 | $2,093,676.45 |
DisclosureSEC source: 0001179110-21-002251 · edgar.xml · nonDerivative · entry 3 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,951 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.25 to $105.24 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 23:28 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 5,192 | $79.02 | $410,271.84 |
DisclosureSEC source: 0001179110-21-002251 · edgar.xml · nonDerivative · entry 2 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,946 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 23:28 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 15,003 | $93.50 | $1,402,780.50 |
DisclosureSEC source: 0001179110-21-002251 · edgar.xml · nonDerivative · entry 1 Sorg Elaine K. · CIK 0001832571 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.